SymPath(R) testing and its look into the intricate workings of the diverse mechanisms of the brain shall considerably reduce a patient's burden during these already difficult times, furnishing physicians with a medically proven test, allowing for precise, effective and speedy diagnosis.
Equally, the SymPath(R) test will also allow major employers and a multitude of organizations within the health industry such as insurance companies, health providers, health establishments and governments in their efforts in reducing inefficiencies and most importantly cost.
To obtain the background scientific documentation concerning SymPath(R), the company shall provide on its website within days and weeks to come, several reports, findings and other such documents.
For more information, do not hesitate to contact us by writing to firstname.lastname@example.org and your request will be transferred to the appropriate persons and we will get back to you as soon as possible.
Contact: Neuro-Biotech Corp. Dr Claude Poulin 41 61 500 05 16 email@example.com www.neuro-biotechcorp.com
Forward Looking Statements
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual
|SOURCE Neuro-Biotech Corp.|
Copyright©2010 PR Newswire.
All rights reserved